Qiagen Stock Price, News & Analysis

QIAGEN (NYSE: QGEN) has raised its full-year 2020 forecast for net sales and adjusted earnings per share, anticipating strong performance in 2021 driven by its focus on five growth pillars. The company also plans to expand its Supervisory Board to enhance expertise in Life Sciences and diagnostics. CEO Thierry Bernard acknowledged the team's efforts during the COVID-19 pandemic, highlighting the launch of new testing solutions and increased production capacity. QIAGEN will host a Virtual Deep Dive on December 8 for a strategic and financial update.

QIAGEN N.V. has launched the QuantiFERON SARS-CoV-2 RUO solution, designed to detect T-cell responses to COVID-19. This innovative technology enables researchers to assess immunity levels and disease progression more effectively, as studies show T-cell responses decline slower than antibody responses. With the ability to indicate disease severity and long-term immunity, this tool enhances QIAGEN's COVID-19 portfolio, which includes sample-preparation technology and PCR testing.

QIAGEN N.V. has entered a strategic collaboration with BioNTech SE to develop a tissue-based companion diagnostic for identifying patients with head and neck squamous cell carcinoma (SCCHN) linked to human papilloma virus (HPV) infections. Utilizing QIAGEN’s RGQ MDx platform, the assay aims to expand its applications across various HPV-related cancers. With over 650,000 new SCCHN cases annually, and projections indicating doubled numbers by 2035, this collaboration positions QIAGEN to enhance its HPV diagnostic offerings, building on its established market leadership.

QIAGEN N.V. (NYSE: QGEN) has launched the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test in Europe, addressing the need for rapid diagnosis during flu season. This multiplex PCR test can differentiate between influenza A and B, RSV, and SARS-CoV-2 in just 80 minutes, aiding healthcare professionals in treatment decisions amidst similar respiratory symptoms. Following CE-IVD registration, the test has also received a request for Emergency Use Authorization from the FDA. The company has additionally expanded the use of saliva samples in its existing SARS-CoV-2 test.

QIAGEN has launched the QIAreach™ SARS-CoV-2 Antigen Test in the U.S., enabling rapid detection of SARS-CoV-2 antigens in 2-15 minutes for active infections. Developed with Ellume, the test can process over 30 samples per hour and offers digital results without subjective interpretation. An EUA application for symptomatic patients has been submitted, with plans for a POC claim later this year. The test addresses the need for scalable and accurate antigen testing as part of COVID-19 strategies, complementing PCR testing for higher throughput.

QIAGEN N.V. (NYSE: QGEN) announced a conference call set for October 28 to discuss third-quarter results for 2020, following the release of their financial report on October 27. The call will be at 14:00 Frankfurt time/13:00 London time/9:00 New York time, hosted by CEO Thierry Bernard and CFO Roland Sackers. Interested participants can join via phone or by accessing the webcast. QIAGEN specializes in Sample to Insight solutions, serving over 500,000 customers globally in Molecular Diagnostics and Life Sciences as of September 30, 2020.

QIAGEN N.V. (NYSE: QGEN) reported robust Q3 2020 results, with sales escalating by 26% to $483.8 million compared to $382.7 million in Q3 2019. Adjusted EPS soared 61% to $0.58. Encouraged by this performance, the company raised its 2020 outlook, forecasting 20% sales growth and adjusted EPS of $2.07-2.09. The significant sales increase is attributed to high demand for COVID-19 related products, alongside other portfolio areas. QIAGEN also expanded its COVID-19 testing capabilities and solidified its position in automated molecular testing through a recent acquisition.

QIAGEN N.V. (NYSE: QGEN) reported strong preliminary results for Q3 2020, with net sales rising 26% year-over-year to $481.3 million, surpassing prior growth forecasts. This growth is attributed to heightened demand for COVID-19 testing solutions, along with improved trends in non-COVID product sales. Adjusted EPS reached approximately $0.58, marking a 61% increase from $0.36 in Q3 2019. QIAGEN anticipates minimal currency impact on its results. Full Q3 results will be published on November 4, 2020, with a conference call scheduled for November 5.

QIAGEN (NYSE: QGEN) has announced a new approach to viral RNA epidemiology with its QIAprep Viral RNA UM Kit. This innovative kit simplifies PCR analysis for SARS-CoV-2 and other RNA viruses, allowing sample preparation in just two minutes. The streamlined process delivers results in under one hour, significantly faster than traditional methods that take about three hours. The kit can manage up to 2,600 samples in an eight-hour shift and minimizes plastic use while reducing reagent and labor costs. Initial studies show detection levels comparable to standard protocols.